

Amendments to the Claims: This listing of claims will replace all prior versions, and listings, of claims in the application

Listing of Claims:

1. - 24. (Canceled)

25. **(Currently Amended)** An isolated recombinant polypeptide comprising:

(a) the amino acid sequence SEQ ID NO:2; or,

(b) an immunogenic fragment of 15 or more contiguous amino acids of SEQ ID NO:2; wherein the immunogenic fragment, when administered to a subject coupled to a suitable carrier or in a suitable composition, which can include an adjuvant ~~or coupling to a suitable carrier~~, is capable of inducing induces an antibody ~~or T-cell mediated immune response that recognizes the polypeptide of~~ that specifically binds to said fragment within SEQ ID NO:2.

26. (Canceled)

27. (Previously Presented) The isolated recombinant polypeptide of claim 25, wherein the polypeptide comprises the amino acid sequence SEQ ID NO:2.

28. (Canceled)

29. **(Currently Amended)** The isolated recombinant polypeptide of claim 25, wherein the polypeptide comprises an immunogenic fragment of 15 or more contiguous amino acids of SEQ ID NO:2; wherein the immunogenic fragment, when administered to a subject coupled to a suitable carrier or in a suitable composition which can include an adjuvant, ~~or coupling to a suitable carrier~~, is capable of inducing induces an antibody ~~or T-cell mediated immune response that recognizes the polypeptide of~~ that specifically binds to said fragment within SEQ ID NO:2.

30. (Canceled)

31. **(Currently Amended)** The isolated recombinant polypeptide of claim 25, wherein the immunogenic fragment of (b) comprises 20 or more contiguous amino acids of SEQ ID NO:2, wherein the immunogenic fragment, when administered to a subject coupled to a suitable carrier or in a suitable composition which can include an adjuvant, ~~or coupling to a suitable carrier~~, is capable of inducing induces an antibody ~~or T-cell mediated immune response that recognizes the polypeptide of~~ that specifically binds to said fragment within SEQ ID NO:2.

32. (Previously Presented) The isolated recombinant polypeptide of claim 25, wherein the isolated recombinant polypeptide consists of SEQ ID NO:2.

33-34. (Canceled)

35. (**Currently Amended**) ~~An isolated recombinant A~~ fusion protein comprising the polypeptide of claim 25.

36. - 39. (Canceled)

40. (Previously Presented) An immunogenic composition comprising the recombinant polypeptide of claim 25 and a pharmaceutically acceptable carrier.

41. (**Currently Amended**) The immunogenic composition of claim 40, wherein the immunogenic composition further comprises at least one other *Neisseria meningitidis* antigen other than a polypeptide comprising SEQ ID NO:2.

42. (Canceled)

43. (**Currently Amended**) A method for inducing an ~~immune response~~ antibody in a mammal comprising ~~administration of~~ administering the isolated recombinant polypeptide of claim 25 to the mammal in an amount effective to induce an antibody.

44. - 47. (Canceled)

48. (**Currently Amended**) ~~An isolated recombinant A~~ fusion protein comprising the polypeptide of claim 27.

49. (**Currently Amended**) An immunogenic composition comprising the isolated recombinant polypeptide of claim 27 and a pharmaceutically acceptable carrier.

50. (**Currently Amended**) ~~An isolated recombinant A~~ fusion protein comprising the polypeptide of claim 29.

51. (**Currently Amended**) An immunogenic composition comprising the isolated recombinant polypeptide of claim 29 and a pharmaceutically acceptable carrier.

52. - 56. (Canceled)

57. **(Currently Amended)** ~~An isolated recombinant A~~ fusion protein comprising the polypeptide of claim 31.
58. **(Canceled)**
59. **(Currently Amended)** An immunogenic composition comprising the isolated recombinant polypeptide of claim 31 and a pharmaceutically acceptable carrier.
60. **(New)** An immunogenic composition comprising the fusion protein of claim 35 and a pharmaceutically acceptable carrier.
61. **(New)** An immunogenic composition comprising the fusion protein of claim 48 and a pharmaceutically acceptable carrier.
62. **(New)** An immunogenic composition comprising the fusion protein of claim 50 and a pharmaceutically acceptable carrier.
63. **(New)** An immunogenic composition comprising the fusion protein of claim 57 and a pharmaceutically acceptable carrier.